Galactooligosaccharides (GOS) and constipation

What 2 graded rows on galactooligosaccharides (gos) agree on for constipation, and where they differ. Counted side by side, never averaged.

Consensus finder Rows from the Galactooligosaccharides (GOS) page, reviewed Oct 21, 2026 How it decides

What the rows agree on

Each block and row is one graded row from the Galactooligosaccharides (GOS) page, with its PubMed record.

Supplement

Galactooligosaccharides (GOS) Choose another

2 rows · 195 people

Split. 1 row found an improvement and 1 had mixed results.

Mixed

Improved

Each block is one evidence row, sized by how many people it enrolled, with its grade inside. Outlined: mixed results.

From the rows

The best-graded row, grade C, is a randomized trial of 132 people (2022) and reported mixed results.

The rows run from 63 to 132 people, published from 2022 to 2024: 2 single studies.

1 improved · 1 mixed

Grade CBowel movements in functional constipation · Improved
RCT · n 63 · 2024 · Adults meeting Rome IV criteria for functional constipation (Korea; 34 GOS, 29 placebo)
Not stated in the abstract · 4 weeks
Bowel movements per day and stool shape improved vs control; constipation-related quality of life satisfaction increased; Bifidobacterium and Lactobacillus rose from baseline. No significant adverse reactions apart from pulse rate.
Row on the Galactooligosaccharides (GOS) page · PubMed 38787732 (opens PubMed)
Grade CStool frequency in self-reported constipation · Mixed
RCT · n 132 · 2022 · Adults aged 18 to 59 with self-reported constipation (94% women)
5.5 g or 11 g/day · 3 weeks
Overall, 11 g showed only a trend toward more frequent stools vs control. In those with 3 or fewer bowel movements a week at baseline and in those aged 35 or over, 11 g increased stool frequency. Faecal Bifidobacterium rose dose-dependently.
Row on the Galactooligosaccharides (GOS) page · PubMed 35057489 (opens PubMed)